INTRODUCTION
Trimethoprim [2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine] prevents the bacterial NADPH-dependent reduction of dihydrofolate to tetrahydrofolate by competitively inhibiting the enzyme dihydrofolate reductase (5,6,7,8-tetrahydrofolate : NADP+ oxidoreductase, EC 1.5.1.3) (Burchall & Hitchings, 1965) . Three years after the introduction of trimethoprim, bacterial plasmids, which were able to resist the action of the drug, emerged in Gram-negative bacteria (Fleming et al., 1972) . The resistance mechanism, encoded by these plasmids, is the synthesis of an additional trimethoprimresistant dihydrofolate reductase, which enables the inhibited target of the host bacterium to be by-passed (Amyes & Smith, 1974a) .
The dihydrofolate reductases encoded by resistance plasmids (R-plasmids) in Gram-negative bacteria have been subdivided into four major classes. The type I enzymes (Mr 35000) are the most common and consist oftwo identical subunits (Mr 18 000). They are heat-labile and have Ki values for trimethoprim of about 20 lSM (Pattishall et al., 1977; Amyes & Smith, 1978; Tennhammar-Ekman & Sk6ld, 1979) . The type II enzymes consist of four subunits, each with an Mr of about 9000 (Smith et al., 1979; Fling & Elwell, 1980 Skold, 1979; Amyes & Smith, 1976) . The third type of enzyme is monomeric (Mr 16900) and is much more sensitive to trimethoprim (Ki 19 nM) (Fling et al., 1982; Joyner et al., 1984) . The type IV enzyme has recently been identified and differs from the other three because it is inducible (Young & Amyes, 1986) . It also has a larger Mr (46700) but a low Ki for trimethoprim (63 nM).
Until 1983, high-degree plasmid-mediated trimethoprim-resistance had only been found in Gram-negative bacteria. Recently, however, some multi-resistant strains of Staphylococcus aureus, which have been responsible for an increasing number of hospital infections in Australia, were also found to be trimethoprim-resistant (Lyon et al., 1983 (Lyon et al., , 1984 . Some of these trimethoprimresistant strains possessed a 28.4 kb plasmid encoding resistance to trimethoprim in addition to acriflavine and quaternary ammonium compounds and the aminoglycosides gentamicin, tobramycin and kamamycin (Townsend et al., 1984; Tennent et al., 1985; Lyon et al., 1986; Gillespie et al., 1986) . Plasmid pSKl, the prototype of these plasmids, has been found in Staphylococcus aureus strains isolated throughout Australia (Lyon et al., 1984) . This plasmid was shown to carry a trimethoprim-resistance gene by mixed-culture transfer and curing studies (Tennent et al., 1985; Lyon et al., 1986) . Like the type I and type II trimethoprim R-plasmids from Gram-negative bacteria, plasmid pSK 1 conferred a high degree of resistance, enabling the host strain to grow in solution containing 800 mg of trimethoprim/l. The trimethoprim-resistance gene of plasmid pSKI, which lies within a 51 kb fragment of the plasmid flanked by two EcoRl restriction sites, has been cloned into the plasmid vector pACYC184 to produce the hybrid plasmid pSK407 (Lyon et al., 1986) .
In the present study we have characterized the dihydrofolate reductase that was specified by the clinical plasmid pSK1 by examining the enzyme encoded by the hybrid plasmid pSK407. The enzyme, designated type S1, differs both physically and biochemically from all previous plasmid dihydrofolate reductases. (Tennent et al., 1985) was introduced by mixed-culture transfer. The trimethoprim-sensitive S. aureus N.C.T.C. 6571 (Amyes & Smith, 1974b) was donated by Pamela M. Waterworth. Escherichia coli K-12 strain BHB2600 (F-803 supEsupFhsdR met) (Hohn, 1979) containing the 4.3 kb tetracycline-and chloramphenicol-resistant cloning vector pACYCI84 (Chang & Cohen, 1978) was used as a trimethoprimsensitive control. Plasmid pSK407 was a hybrid plasmid of pACYC184 containing the 5.1 kb EcoRl restriction fragment of plasmid pSKl that possessed the trimethoprim-resistance structural gene (Lyon et al., 1986) . Enzyme preparation and assay
MATERIALS
For the determinations of specific activity, dihydrofolate reductase was prepared from 1-litre overnight cultures of bacteria grown in Oxoid Isosensitest broth with vigorous agitation at 37°C as detailed by Young & Amyes (1986) . The cells were harvested by centrifugation (6000 g for 10 min at 15°C) and resuspended in buffer A (50 mM-sodium phosphate buffer, pH 7.4, containing 10 mM-2-mercaptoethanol and 1 mM-EDTA). The bacteria were disrupted by sonication, and the cell debris was removed by centrifugation (40000 g for 1 h at 4°C). Dihydrofolate reductase activity was assayed at 30°C in 40 mM-sodium phosphate buffer, pH 6, as described previously (Amyes & Smith, 1974a (1956) . For enzyme purification, 5-litre cultures were prepared as above. (NH4)2SO4 was added to 5000 saturation. After centrifugation (14000 g for 30 min at 4°C), further (NH4)2SO4 was added to the supernatant to give 80% saturation, and, after further centrifugation, the pellet was dialysed against buffer A. It was applied to a Sephadex G-75 column (2 cm2 x 90 cm) previously equilibrated with buffer A and eluted with the same buffer (Young & Amyes, 1986) . The Mr was determined by Sephadex exclusion chromatography as described previously (Amyes & Smith, 1974a) . Heat-sensitivity, enzyme kinetics and inhibitor studies were performed as previously described (Amyes & Smith, 1976) .
RESULTS
S. aureus SK2267 (pSK1) from E. coli BHB2600 (pSK407) were grown both in the presence and in the absence of trimethoprim (10 mg/l). S. aureus N.C.T.C. 6571 and E. coli BHB2600 (pACYCI84) were cultured solely in the absence of the drug. The specific activities of dihydrofolate reductase in the cleared lysates are shown in Table 1 . The control E. coli strain BHB2600 (pACYC1 84), which lacked any trimethoprim-resistance gene, had a dihydrofolate reductase specific activity of 1.7 nmol of dihydrofolate reduced/min per mg of protein. On the other hand, the specific activity of the control trimethoprim-sensitive S. aureus strain was about 7 times greater. The presence of the trimethoprimresistance gene in S. aureus considerably increased the specific activity of dihydrofolate reductase. A similar increase was found in the E. coli strain harbouring the hybrid trimethoprim-resistance plasmid pSK407. In all cases, the production of dihydrofolate reductase was constitutive, and no significant increase in activity was observed when the strains were grown in the presence of trimethoprim. Since the chromosomal dihydrofolate reductase activity of S. aureus was high and could affect the purification of the plasmid enzyme, the dihydrofolate reductase of the hybrid plasmid, pSK407, was purified and its properties were compared with those of the Dihydrofolate reductase activity was purified from E. coli BHB2600 (pSK407) grown in the presence of 10 mg of trimethoprim/l and from S. aureus N.C.T.C. 6571 grown in the absence of the drug. Both preparations gave a single peak of dihydrofolate reductase activity after Sephadex gel filtration. The plasmid enzyme peak is shown in Fig. 1 . In an attempt to distinguish the plasmid enzyme from the E. coli host dihydrofolate reductase, the assays were repeated in the presence of 4 /tM-trimethoprim, a concentration sufficient to eliminate chromosomal dihydrofolate reductase activity. The peak was decreased slightly, but the maximum enzyme activity was still found at the same position (results not shown). When the peak from S. aureus N.C.T.C. 6571 was assayed in the same concentration of trimethoprim, no enzyme activity could be seen. When the gel filtrations were repeated in the presence of standard proteins, the peak of activity for the plasmid dihydrofolate reductase corresponded to an Mr of 19700 (Fig. 1) , whereas the enzyme peak for S. aureus N.C.T.C 6571 corresponded to 21 600. The failure to detect a second peak of activity identifiable as the host enzyme in the E. coli BHB2600 (pSK407) preparation was probably due to the large amount of plasmid-determined enzyme present and its similar size to the E. coli enzyme (Amyes & Smith, 1974a) .
The peak fraction of the plasmid enzyme (59) had a specific activity of 815.0, which represented a greater than 20-fold purification of the crude extract, and the peak fraction of the S. aureus chromosomal enzyme (57) had a specific activity of 484.7, which represented a greater than 30-fold purification. These two fractions were used in the further characterization of the enzymes. The plasmid enzyme was heat-stable, retaining more than 70% of its activity after maintenance for 12 min at 45°C, as was the chromosomal enzyme, which retained 100% of its activity under the same conditions ( Table 2 ).
The activities of both enzymes were assayed in the presence of increasing concentrations of trimethoprim and methotrexate in order to determine the concentration of each antifolate required to give 50% inhibition (ID50).
The ID50 of trimethoprim for the plasmid enzyme was 50 1M and that of methotrexate was 2 nm. In both cases the enzyme activity was inversely proportional to the logarithm of the inhibitor concentration. The corresponding values for the S. aureus chromosomal enzyme were 40 nm for trimethoprim and 2.5 nm for methotrexate ( Table 2 ).
The activity of the peak fractions was investigated under conditions of partial saturation with dihydrofolate and full saturation with NADPH (50 mM). In control studies we have found that concentrations of NADPH above 10 mm do not limit the rate of either of these enzymes. The results, analysed by the method of Lineweaver & Burk, show that the Km value for dihydrofolate of the plasmid enzyme (Fig. 2 ) was 10.8 gM. This is similar to the type I, type II and type IV Gram-negative plasmid dihydrofolate reductases but is about 25-fold greater than the value obtained with the type III enzyme (Amyes, 1986) . The S. aureus chromosomal enzyme had a higher Km for dihydrofolate than those of the new plasmid enzyme and the E. coli chromosomal dihydrofolate reductase. When the assays were repeated in the presence of trimethoprim it was found that the maximum velocity of the plasmid dihydrofolate reductase remained the same (Fig. 2) , indicating that the drug causes competitive inhibition of the enzyme. The Ki for trimethoprim was 11.6 /tM, similar to that reported for the type I enzyme (Pattishall et al., 1977) . Trimethoprim also competitively inhibited the S. aureus chromosomal dihydrofolate reductase, with a Ki of 6.5 nM, similar to that of the E. coli host enzyme (Amyes & Smith, 1976) . Vol. 243 DISCUSSION The properties of the S. aureus plasmid dihydrofolate reductase characterized here show marked differences from the four types of Gram-negative plasmiddetermined enzymes (for review see Amyes, 1986) . This is the first plasmid dihydrofolate reductase from staphylococci to be identified and characterized, and we therefore describe it as the type SI.
The Mr of the type SI enzyme is similar to that of the S. aureus chromosomal enzyme. However, the other properties of the SI dihydrofolate reductase suggest that it is not related to the chromosomal enzyme. In addition, genetic probing experiments with the trimethoprimresistance gene from pSK 1 failed to show homology with the bacterial chromosome of sensitive staphylococci (L. Loo & R. A. Skurray, unpublished work).
The structural gene encoding the type SI dihydrofolate reductase has been shown, by transposon mutagenesis of the cloned gene in the hybrid plasmid pSK407, to be a maximum of 0.75 kb and a minimum of 0.55 kb. This gene could be predicted to encode a protein with an Mr between about 20000 and 27000 (Lyon et al., 1986) . The actual size of the plasmid enzyme is very close to the minimum predicted from the size of the structural gene, and this fact suggests that the whole of the dihydrofolate reductase is encoded by the gene and that it is not made up of identical subunits, as are the type I and type II Gram-negative plasmid enzymes. In this one respect, the SI dihydrofolate reductase is like the type III plasmid enzyme.
In its physical properties, the SI enzyme is most similar to the type I Gram-negative plasmid dihydrofolate reductase and, more especially, the smaller type lb variant (Young & Amyes, 1985) . It has an equivalent Km value for dihydrofolate and Ki for trimethoprim. It also has approximately the same ID50 value for trimethoprim, but surprisingly has the same ID50 value for methotrexate as the S. aureus chromosomal enzyme. The type I enzyme is produced constitutively in amounts up to 10 times that of the E. coli chromosomal enzyme. Similarly, the SI enzyme is produced in the same order of magnitude relative to the S. aureus chromosomal enzyme. However, the enzymes are probably not directly related to each other. They have very different responses to heat treatment, and, unlike the type I enzyme, the SI dihydrofolate reductase does not seem to be made up of identical subunits. In addition, an S. aureus plasmidencoded trimethoprim-resistance gene, which hybridized with the Australian trimethoprim-resistance gene, showed no homology with the type I plasmid dihydrofolate reductase structural gene (Archer et al., 1986) .
The type I plasmid gene is by far the most widespread plasmid dihydrofolate reductase structural gene in Gram-negative bacteria. In many respects, the biochemical properties of the SI gene product are similar to the type I gene product, and, although they are not directly related to one another, the two genes do seem to have evolved convergently to produce dihydrofolate reductases with similar trimethoprim-resistance characteristics. Future studies will show if the type SI dihydrofolate reductase gene shares the same promiscuity as the type I Gram-negative structural gene.
